292 related articles for article (PubMed ID: 27587250)
1. [Efficacy and safety analysis of different dose idarubicin plus cytarabine regimen as induction chemotherapy for young patients with de-novo acute myeloid leukemia].
Zhang Y; Yao XM; Zhu SL; Suo SS; Mao LP; Wei JY; Yu WJ; Mai WY; Tong HY; Meng HT; Qian WB; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2016 Aug; 37(8):682-7. PubMed ID: 27587250
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and safety of IA regimen containing different doses of idarubicin in de-novo acute myeloid leukemia for adult patients].
Sun AN; Tian XP; Cao XS; Ouyang J; Gu J; Xu KL; Yu K; Zeng QS; Sun ZM; Chen GA; Gao SJ; Zhou J; Wang JH; Yang LH; Luo JM; Zhang M; Guo XH; Wang XM; Zhang X; Shi KQ; Sun H; Ding XM; Hu JD; Zheng RJ; Zhao HG; Hou M; Wang X; Chen FP; Zhu Y; Liu H; Huang DP; Liao AJ; Ma LM; Su LP; Liu L; Zhou ZP; Huang XB; Sun XM; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1017-1023. PubMed ID: 29365393
[No Abstract] [Full Text] [Related]
3. The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.
Wang H; Xiao X; Xiao Q; Lu Y; Wu Y
Medicine (Baltimore); 2020 Jun; 99(24):e20094. PubMed ID: 32541448
[TBL] [Abstract][Full Text] [Related]
4. The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.
Chen Y; Yang T; Zheng X; Yang X; Zheng Z; Zheng J; Liu T; Hu J
Medicine (Baltimore); 2016 Jul; 95(30):e4182. PubMed ID: 27472687
[TBL] [Abstract][Full Text] [Related]
5. Addition of Cladribine to Idarubicin and Cytarabine during Induction Increases the Overall Efficacy Rate in Adult Patients with Acute Myeloid Leukemia: A Matched-Pair Retrospective Comparison.
Shen Y; Chen J; Liu Y; Wu D
Chemotherapy; 2014; 60(5-6):368-74. PubMed ID: 26496511
[TBL] [Abstract][Full Text] [Related]
6. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Qin T; Xu Z; Zhang Y; Lin Y; Ru K; Fang L; Zhang H; Pan L; Hu N; Qu S; Wang J; Xing R; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):94-9. PubMed ID: 27014976
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of 10 mg/m² or 8 mg/m² idarubicin plus cytarabine regimen as induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia].
Zhang Y; Yang S; Wang J; Zhu H; Bao L; Jia J; Zhao T; Jiang H; Lu J; Jiang B; Huang X; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2015 Mar; 36(3):225-9. PubMed ID: 25854467
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
[TBL] [Abstract][Full Text] [Related]
9. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
Nazha A; Kantarjian H; Ravandi F; Huang X; Choi S; Garcia-Manero G; Jabbour E; Borthakur G; Kadia T; Konopleva M; Cortes J; Ferrajoli A; Kornblau S; Daver N; Pemmaraju N; Andreeff M; Estrov Z; Du M; Brandt M; Faderl S
Am J Hematol; 2013 Nov; 88(11):961-6. PubMed ID: 23877926
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study on combination of homoharringtonine, Ara-C and idarubicin induction for treatment of newly diagnosed acute myeloid leukemia patients].
Qin TJ; Xu ZF; Fang LW; Zhang HL; Zhang Y; Wang JZ; Pan LJ; Hu NB; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1277-82. PubMed ID: 22040988
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of the efficacy of IA and HAD induction regimens in the treatment of patients with newly diagnosed acute myeloid leukemia: a single-center study].
Zhang CX; Qiu SW; Gong BF; Gong XY; Li Y; Liu YT; Fang QY; Zhang GJ; Liu KQ; Zhou CL; Wei SN; Lin D; Liu BC; Wang Y; Mi YC; Wei H; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):383-387. PubMed ID: 35680595
[No Abstract] [Full Text] [Related]
12. Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia.
Duan W; Yang S; Zhao T; Hu L; Qin Y; Jia J; Wang J; Lu S; Jiang H; Zhang X; Xu L; Wang Y; Lai Y; Shi H; Huang X; Jiang Q
Ann Hematol; 2023 Oct; 102(10):2695-2705. PubMed ID: 37572135
[TBL] [Abstract][Full Text] [Related]
13. Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
Parovichnikova EN; Loukianova IA; Troitskaya VV; Drokov MY; Lobaova TI; Kuzmina LA; Sokolov AN; Kokhno AV; Fidarova ZT; Baskhaeva GA; Gavrilina OA; Vasilyeva VA; Obukhova TN; Kuznetsova SA; Sudarikov AB; Dvirnik VN; Galtseva IV; Davidiva JO; Kulikov SM; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):14-22. PubMed ID: 30701918
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
15. [Outcomes of adult patients with
Ren X; Zhao T; Wang J; Zhu HH; Jiang H; Jia JS; Yang SM; Jiang B; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2018 Jan; 39(1):15-21. PubMed ID: 29551027
[No Abstract] [Full Text] [Related]
16. Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.
Jin J; Chen J; Suo S; Qian W; Meng H; Mai W; Tong H; Huang J; Yu W; Wei J; Lou Y
Leuk Lymphoma; 2015 Jun; 56(6):1691-7. PubMed ID: 25257348
[TBL] [Abstract][Full Text] [Related]
17. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Li X; Xu S; Tan Y; Chen J
Cochrane Database Syst Rev; 2015 Jun; (6):CD010432. PubMed ID: 26037486
[TBL] [Abstract][Full Text] [Related]
18. [Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
Parovichnikova EN; Troitskaia VV; Kliasova GA; Kuz'mina LA; Sokolov AN; Paramonova EV; Galstian GM; Kessel'man SA; Drokov MIu; Vasil'eva VA; Obukhova TN; Kulikov SM; Savchenko VG
Ter Arkh; 2014; 86(7):14-23. PubMed ID: 25314773
[TBL] [Abstract][Full Text] [Related]
19. Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia.
Choi EJ; Lee JH; Lee JH; Park HS; Ko SH; Hur EH; Moon J; Goo BK; Kim Y; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH
Leuk Res; 2018 May; 68():51-56. PubMed ID: 29544132
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia.
Lei M; Liu L; Wang Z; Wu D
Indian J Cancer; 2019; 56(2):167-172. PubMed ID: 31062738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
